SCHEMBL14764498

SCHEMBL14764498

Cc1nc2cccnc2n2c(-c3ccccc3Cl)nnc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 20/20 1.00
PDE10A Q9Y233 18/20 0.72
PDE4D Q08499 1/20 0.62
PDE11A Q9HCR9 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14764560 0.86 PDE2A (0.76) PDE2APDE10A
SCHEMBL20018180 0.86 PDE2A (0.79) PDE2APDE10A
SCHEMBL14764577 0.85 PDE2A (0.74) PDE2APDE10A
SCHEMBL15471737 0.84 PDE2A (1.00) PDE2APDE10A
SCHEMBL14764405 0.84 PDE2A (0.72) PDE2APDE10A
SCHEMBL15471981 0.84 PDE2A (0.76) PDE2APDE10A
SCHEMBL15471793 0.83 PDE2A (0.70) PDE2APDE10A
SCHEMBL12502893 0.82 PDE2A (1.00) PDE2APDE10APDE4DPDE11A
SCHEMBL15471794 0.82 PDE2A (0.72) PDE2APDE10A
SCHEMBL14764467 0.82 PDE2A (0.70) PDE2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9056863-B2 Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof H. LUNDBECK A/S (DK) 2015-06-16 US claimed
US-20140235645-A1 Pyridine Compounds and Uses Thereof H. LUNDBECK A/S (DK) 2014-08-21 US claimed
EP-2763989-A1 PYRIDINE COMPOUNDS AND USES THEREOF H. Lundbeck A/S (DK) 2014-08-13 EP claimed
WO-2013034761-A1 PYRIDINE COMPOUNDS AND USES THEREOF H. LUNDBECK A/S (DK) 2013-03-14 WO claimed
US-11419874-B2 Treatment of tachycardia OSLO UNIVERSITY HOSPITAL HF (NO) 2022-08-23 US disclosed
US-20200345744-A1 TREATMENT OF TACHYCARDIA OSLO UNIVERSITY HOSPITAL HF (NO) 2020-11-05 US disclosed
US-9056863-B2 Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof H. LUNDBECK A/S (DK) 2015-06-16 US disclosed
US-9056863-B2 Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof H. LUNDBECK A/S (DK) 2015-06-16 US disclosed
US-9056863-B2 Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof H. LUNDBECK A/S (DK) 2015-06-16 US disclosed
US-20140235645-A1 Pyridine Compounds and Uses Thereof H. LUNDBECK A/S (DK) 2014-08-21 US disclosed
US-20140235645-A1 Pyridine Compounds and Uses Thereof H. LUNDBECK A/S (DK) 2014-08-21 US disclosed
US-20140235645-A1 Pyridine Compounds and Uses Thereof H. LUNDBECK A/S (DK) 2014-08-21 US disclosed
EP-2763989-A1 PYRIDINE COMPOUNDS AND USES THEREOF H. Lundbeck A/S (DK) 2014-08-13 EP disclosed
WO-2013034761-A1 PYRIDINE COMPOUNDS AND USES THEREOF H. LUNDBECK A/S (DK) 2013-03-14 WO disclosed
WO-2013034761-A1 PYRIDINE COMPOUNDS AND USES THEREOF H. LUNDBECK A/S (DK) 2013-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235645-A1 Pyridine Compounds and Uses Thereof ATP6V1B2, NDUFS5, MT-ND5 PDE2A 719/4885PDE10A 476/4885PDE4D 393/4885
US-11419874-B2 Treatment of tachycardia PDE4B, PDE2A, PDE5A PDE2A 2/4885PDE10A 65/4885PDE4D 10/4885
US-20200345744-A1 TREATMENT OF TACHYCARDIA PDE4B, PDE2A, PDE5A PDE2A 2/4885PDE10A 65/4885PDE4D 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.